Please assess the completion status of the following clinical trial:

Trial Title: ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive by licensed diagnostic test with presumed duration of infection \> 6 months from date of randomisation.~* Aged \> 16 years of age (or minimum age as determined by local regulations or as legal requirements dictate).~* Antiretroviral treatment naïve.~* Qualifying plasma HIV RNA \> 2,000 copies/mL and a CD4+ T cell count of ≥ 50 cells/µL.~* No evidence of harbouring a drug resistant HIV (based upon genotypic drug testing).~* Calculated creatinine clearance (CLCr) greater than or equal to 70 mL/min (Cockcroft-Gault formula).~* Able to provide written informed consent.~Exclusion Criteria:~* The following laboratory variables,~  * absolute neutrophil count (ANC) \< 750 cells/µL~ * haemoglobin \< 8.0 g/dL~ * platelet count \< 50,000 cells/µL~ * serum AST, ALT \> 5 x upper limit of normal (ULN)~ * serum bilirubin \> 1.5 x ULN~* Pregnant or nursing mothers.~* Current use of human growth hormone, testosterone or other anabolic steroid.~* Current use of any prohibited medications as described in product specific information.~* Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation.~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.~* Patients unlikely to be able to remain in follow-up for the protocol-defined period.~* Patients with known renal insufficiency.~* Patients with obstructive liver disease.~* Patients with intractable diarrhoea (six loose stools/day for at least seven consecutive days).~* History of acute or chronic pancreatitis.~* Presence of cardiomyopathy (due to any cause) or any significant cardiovascular disease, such as unstable ischemic heart disease.~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
- 2 (Type: ACTIVE_COMPARATOR): Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
- 3 (Type: EXPERIMENTAL): Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)

Based on this trial design, predict the completion outcome and termination type (if applicable).